{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "14", "@year": "2020", "@timestamp": "2020-01-14T07:23:13.000013-05:00", "@month": "01"}, "ait:date-sort": {"@day": "01", "@year": "2016", "@month": "06"}}, "xocs:meta": {"xocs:funding-list": {"@pui-match": "primary", "@has-funding-info": "1", "xocs:funding": {"xocs:funding-agency-acronym": "JSPS", "xocs:funding-agency": "Japan Society for the Promotion of Science", "xocs:funding-id": "15H05289", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100001691", "xocs:funding-agency-country": "http://sws.geonames.org/1861060/"}, "xocs:funding-addon-generated-timestamp": "2021-02-02T08:23:09.205641Z", "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Research Unit of Hepatitis and Liver Cancer"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "113742843"}, "@dptid": "113742843"}, "author": [{"ce:given-name": "Natthaya", "preferred-name": {"ce:given-name": "Natthaya", "ce:initials": "N.", "ce:surname": "Chuaypen", "ce:indexed-name": "Chuaypen N."}, "@seq": "1", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Chuaypen", "@auid": "55885029700", "ce:indexed-name": "Chuaypen N."}, {"ce:given-name": "Sunchai", "preferred-name": {"ce:given-name": "Sunchai", "ce:initials": "S.", "ce:surname": "Payungporn", "ce:indexed-name": "Payungporn S."}, "@seq": "3", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:surname": "Payungporn", "@auid": "6507400304", "ce:indexed-name": "Payungporn S."}, {"ce:given-name": "Pisit", "preferred-name": {"ce:given-name": "Pisit", "ce:initials": "P.", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}, "@seq": "7", "ce:initials": "P.", "@_fa": "true", "@type": "auth", "ce:degrees": "M.D", "ce:surname": "Tangkijvanich", "@auid": "7003646635", "ce:indexed-name": "Tangkijvanich P."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Center of Excellence in Clinical Virology"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "104425854"}, "@dptid": "104425854"}, "author": [{"ce:given-name": "Nawarat", "preferred-name": {"ce:given-name": "Nawarat", "ce:initials": "N.", "ce:surname": "Posuwan", "ce:indexed-name": "Posuwan N."}, "@seq": "2", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Posuwan", "@auid": "26653756700", "ce:indexed-name": "Posuwan N."}, {"ce:given-name": "Yong", "preferred-name": {"ce:given-name": "Yong", "ce:initials": "Y.", "ce:surname": "Poovorawan", "ce:indexed-name": "Poovorawan Y."}, "@seq": "6", "ce:initials": "Y.", "@_fa": "true", "@type": "auth", "ce:surname": "Poovorawan", "@auid": "7102786191", "ce:indexed-name": "Poovorawan Y."}]}, {"affiliation": {"country": "Japan", "@afid": "60004321", "@country": "jpn", "city": "Nagoya", "organization": [{"$": "Department of Virology and Liver Unit"}, {"$": "Nagoya City University Graduate School of Medical Sciences"}], "affiliation-id": {"@afid": "60004321", "@dptid": "108250313"}, "@dptid": "108250313"}, "author": [{"ce:given-name": "Yasuhito", "preferred-name": {"ce:given-name": "Yasuhito", "ce:initials": "Y.", "ce:surname": "Tanaka", "ce:indexed-name": "Tanaka Y."}, "@seq": "4", "ce:initials": "Y.", "@_fa": "true", "@type": "auth", "ce:surname": "Tanaka", "@auid": "7405315865", "ce:indexed-name": "Tanaka Y."}, {"ce:given-name": "Noboru", "preferred-name": {"ce:given-name": "Noboru", "ce:initials": "N.", "ce:surname": "Shinkai", "ce:indexed-name": "Shinkai N."}, "@seq": "5", "ce:initials": "N.", "@date-locked": "2017-04-05T02:15:44.929", "@_fa": "true", "@type": "auth", "ce:surname": "Shinkai", "@auid": "7003826116", "ce:indexed-name": "Shinkai N."}]}], "citation-title": "Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B", "abstracts": "\u00a9 2016 John Wiley & Sons A/S.Background & Aims: The role of quantitative serum hepatitis B core-related antigen (HBcrAg) in patients with chronic hepatitis B (CHB) receiving pegylated interferon (PEG-IFN) is unclear. This study was aimed at comparing its usefulness with quantitative HBsAg in patients with HBeAg-positive CHB receiving PEG-IFN therapy. Methods: A total 46 patients treated with PEG-IFN for 48 weeks were retrospectively analysed. Intrahepatic covalently closed circular DNA (cccDNA) from paired liver biopsies and serial serum HBsAg and HBcrAg during therapy were assessed. Results: Virological response (VR), defined as HBeAg clearance and HBV DNA <2000 IU/ml at 24 weeks post treatment, was achieved in 15 (32.6%) patients. Responders had significantly higher cccDNA decline from baseline compared with non-responders. Baseline HBsAg and HBcrAg were correlated with cccDNA (r = 0.424, P = 0.020 and r = 0.564, P = 0.001, respectively), and changes in the corresponding markers during therapy were correlated with cccDNA reduction (r = 0.579, P = 0.001 and r = 0.503, P = 0.005, respectively). Responders showed more rapid decline of both markers during therapy compared with non-responders. In multivariate analysis, serum HBcrAg at week 12 was identified as a predictor of VR. The optimal cut-off value for HBcrAg (log10 8.0 U/ml) provided negative predictive value (NPV) of achieving VR at weeks 12 and 24 of 94.4 and 100%, respectively, while using HBsAg > 20 000 IU/ml provided NPV of 80 and 100% respectively. Conclusions: The convenient quantitative HBcrAg represented a reliable marker of intrahepatic cccDNA. Monitoring HBcrAg levels during PEG-IFN therapy may help identify patients with a very low probability of response comparable to, if not better than, quantitative HBsAg.", "correspondence": {"affiliation": {"country": "Thailand", "address-part": "Rama IV road", "postal-code": "10330", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Research Unit of Hepatitis and Liver Cancer"}, {"$": "Department of Biochemistry"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}]}, "person": {"ce:given-name": "Pisit", "ce:initials": "P.", "ce:degrees": "M.D", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}}, "citation-info": {"author-keywords": {"author-keyword": [{"$": "HBsAg quantification", "@xml:lang": "eng"}, {"$": "Hepatitis B core-related antigen", "@xml:lang": "eng"}, {"$": "Hepatitis B virus", "@xml:lang": "eng"}, {"$": "Pegylated interferon", "@xml:lang": "eng"}]}, "citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"website": {"ce:e-address": {"$": "http://www.wiley.com/bw/journal.asp?ref=1478-3223", "@type": "email"}}, "translated-sourcetitle": {"$": "Liver International", "@xml:lang": "eng"}, "volisspag": {"voliss": {"@volume": "36", "@issue": "6"}, "pagerange": {"@first": "827", "@last": "836"}}, "@type": "j", "sourcetitle": "Liver International", "publicationdate": {"month": "06", "year": "2016", "date-text": {"@xfab-added": "true", "$": "1 June 2016"}, "day": "01"}, "codencode": "LIINC", "sourcetitle-abbrev": "Liver Int.", "@country": "gbr", "issn": [{"$": "14783231", "@type": "electronic"}, {"$": "14783223", "@type": "print"}], "publicationyear": {"@first": "2016"}, "publisher": {"publishername": "Blackwell Publishing Ltd", "ce:e-address": {"$": "customerservices@oxonblackwellpublishing.com", "@type": "email"}}, "@srcid": "25321"}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "CABSCLASS", "classification": [{"classification-code": "86.5.1", "classification-description": "IMMUNOLOGY AND INFECTIOUS DISEASES; HUMORAL MEDIATORS OF IMMUNE RESPONSE; Interferon"}, {"classification-code": "86.7.4.9", "classification-description": "IMMUNOLOGY AND INFECTIOUS DISEASES; IMMUNITY TO INFECTION; Medical and Veterinary Virology; Antigens"}]}, {"@type": "EMCLASS", "classification": [{"classification-code": "37", "classification-description": "Drug Literature Index"}, {"classification-code": "48", "classification-description": "Gastroenterology"}]}, {"@type": "ASJC", "classification": "2721"}, {"@type": "SUBJABBR", "classification": "MEDI"}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": "198153-51-4", "chemical-name": "peginterferon alpha2a"}, {"cas-registry-number": "215647-85-1", "chemical-name": "peginterferon alpha2b"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "Antiviral Agents"}, {"chemical-name": "Biomarkers"}, {"chemical-name": "DNA, Circular"}, {"chemical-name": "DNA, Viral"}, {"chemical-name": "Hepatitis B Core Antigens"}, {"chemical-name": "Hepatitis B e Antigens"}, {"chemical-name": "Hepatitis B Surface Antigens"}, {"chemical-name": "Interferons"}]}]}}}, "item-info": {"copyright": {"$": "Copyright 2017 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "dbcollection": [{"$": "CABS"}, {"$": "EMBASE"}, {"$": "MEDL"}, {"$": "REAXYSCAR"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "15", "@year": "2017", "@timestamp": "BST 16:16:55", "@month": "12"}}, "itemidlist": {"itemid": [{"$": "610369463", "@idtype": "PUI"}, {"$": "2016181613", "@idtype": "CABS"}, {"$": "650414228", "@idtype": "CAR-ID"}, {"$": "20160373818", "@idtype": "EMBASE"}, {"$": "26678018", "@idtype": "MEDL"}, {"$": "20161187427", "@idtype": "REAXYSCAR"}, {"$": "84966783616", "@idtype": "SCP"}, {"$": "84966783616", "@idtype": "SGR"}, {"$": "619695810", "@idtype": "PUIsecondary"}], "ce:doi": "10.1111/liv.13046"}}, "tail": {"bibliography": {"@refcount": "37", "reference": [{"ref-fulltext": "Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384: 2053-63.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Hepatitis B virus infection"}, "refd-itemidlist": {"itemid": {"$": "84919848147", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "384"}, "pagerange": {"@first": "2053", "@last": "2063"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Trepo", "ce:indexed-name": "Trepo C."}, {"@seq": "2", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Chan", "ce:indexed-name": "Chan H.L."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Lok", "ce:indexed-name": "Lok A."}]}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Management of hepatitis B: summary of a clinical research workshop"}, "refd-itemidlist": {"itemid": {"$": "34247194561", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "45"}, "pagerange": {"@first": "1056", "@last": "1075"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.H.", "@_fa": "true", "ce:surname": "Hoofnagle", "ce:indexed-name": "Hoofnagle J.H."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Doo", "ce:indexed-name": "Doo E."}, {"@seq": "3", "ce:initials": "T.J.", "@_fa": "true", "ce:surname": "Liang", "ce:indexed-name": "Liang T.J."}, {"@seq": "4", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Fleischer", "ce:indexed-name": "Fleischer R."}, {"@seq": "5", "ce:initials": "A.S.", "@_fa": "true", "ce:surname": "Lok", "ce:indexed-name": "Lok A.S."}]}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Asselah T, Lada O, Moucari R, et al. Interferon therapy for chronic hepatitis B. Clin Liver Dis 2007; 11: 839-49.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Interferon therapy for chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "35648945243", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "11"}, "pagerange": {"@first": "839", "@last": "849"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Asselah", "ce:indexed-name": "Asselah T."}, {"@seq": "2", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Lada", "ce:indexed-name": "Lada O."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Moucari", "ce:indexed-name": "Moucari R."}], "et-al": null}, "ref-sourcetitle": "Clin Liver Dis"}}, {"ref-fulltext": "Vlachogiannakos J, Papatheodoridis GV. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? Liver Int 2015; 35(Suppl. 1): 100-6.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?"}, "refd-itemidlist": {"itemid": {"$": "84919683886", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "35"}, "pagerange": {"@first": "100", "@last": "106"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Vlachogiannakos", "ce:indexed-name": "Vlachogiannakos J."}, {"@seq": "2", "ce:initials": "G.V.", "@_fa": "true", "ce:surname": "Papatheodoridis", "ce:indexed-name": "Papatheodoridis G.V."}]}, "ref-sourcetitle": "Liver Int"}}, {"ref-fulltext": "Suzuki F, Arase Y, Suzuki Y, et al. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol 2012; 47: 814-22.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan"}, "refd-itemidlist": {"itemid": {"$": "84865041484", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "47"}, "pagerange": {"@first": "814", "@last": "822"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Suzuki", "ce:indexed-name": "Suzuki F."}, {"@seq": "2", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Arase", "ce:indexed-name": "Arase Y."}, {"@seq": "3", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Suzuki", "ce:indexed-name": "Suzuki Y."}], "et-al": null}, "ref-sourcetitle": "J Gastroenterol"}}, {"ref-fulltext": "Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-8.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response"}, "refd-itemidlist": {"itemid": {"$": "36549058611", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5"}, "pagerange": {"@first": "1462", "@last": "1468"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Chan", "ce:indexed-name": "Chan H.L."}, {"@seq": "2", "ce:initials": "V.W.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong V.W."}, {"@seq": "3", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "Tse", "ce:indexed-name": "Tse A.M."}], "et-al": null}, "ref-sourcetitle": "Clin Gastroenterol Hepatol"}}, {"ref-fulltext": "Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int 2014; 34(Suppl. 1): 97-107.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "HBsAg quantification: useful for monitoring natural history and treatment outcome"}, "refd-itemidlist": {"itemid": {"$": "84890865948", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "34"}, "pagerange": {"@first": "97", "@last": "107"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Martinot-Peignoux", "ce:indexed-name": "Martinot-Peignoux M."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lapalus", "ce:indexed-name": "Lapalus M."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Asselah", "ce:indexed-name": "Asselah T."}, {"@seq": "4", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Marcellin", "ce:indexed-name": "Marcellin P."}]}, "ref-sourcetitle": "Liver Int"}}, {"ref-fulltext": "Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013a; 58: 872-80.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels"}, "refd-itemidlist": {"itemid": {"$": "84883257597", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "58"}, "pagerange": {"@first": "872", "@last": "880"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Sonneveld", "ce:indexed-name": "Sonneveld M.J."}, {"@seq": "2", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Hansen", "ce:indexed-name": "Hansen B.E."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Piratvisuth", "ce:indexed-name": "Piratvisuth T."}], "et-al": null}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007; 45: 3942-7.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection"}, "refd-itemidlist": {"itemid": {"$": "37249092014", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "45"}, "pagerange": {"@first": "3942", "@last": "3947"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.K.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong D.K."}, {"@seq": "2", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Tanaka", "ce:indexed-name": "Tanaka Y."}, {"@seq": "3", "ce:initials": "C.L.", "@_fa": "true", "ce:surname": "Lai", "ce:indexed-name": "Lai C.L."}], "et-al": null}, "ref-sourcetitle": "J Clin Microbiol"}}, {"ref-fulltext": "Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009; 81: 27-33.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients"}, "refd-itemidlist": {"itemid": {"$": "58149250976", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "81"}, "pagerange": {"@first": "27", "@last": "33"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Suzuki", "ce:indexed-name": "Suzuki F."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Miyakoshi", "ce:indexed-name": "Miyakoshi H."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Kobayashi", "ce:indexed-name": "Kobayashi M."}, {"@seq": "4", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Kumada", "ce:indexed-name": "Kumada H."}]}, "ref-sourcetitle": "J Med Virol"}}, {"ref-fulltext": "Matsuzaki T, Tatsuki I, Otani M, et al. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. J Gastroenterol Hepatol 2013; 28: 1217-22.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation"}, "refd-itemidlist": {"itemid": {"$": "84879458710", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "28"}, "pagerange": {"@first": "1217", "@last": "1222"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Matsuzaki", "ce:indexed-name": "Matsuzaki T."}, {"@seq": "2", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Tatsuki", "ce:indexed-name": "Tatsuki I."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Otani", "ce:indexed-name": "Otani M."}], "et-al": null}, "ref-sourcetitle": "J Gastroenterol Hepatol"}}, {"ref-fulltext": "Seto WK, Wong DK, Fung J, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect 2014; 20: 1173-80.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84917675883", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "20"}, "pagerange": {"@first": "1173", "@last": "1180"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.K.", "@_fa": "true", "ce:surname": "Seto", "ce:indexed-name": "Seto W.K."}, {"@seq": "2", "ce:initials": "D.K.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong D.K."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Fung", "ce:indexed-name": "Fung J."}], "et-al": null}, "ref-sourcetitle": "Clin Microbiol Infect"}}, {"ref-fulltext": "Maasoumy B, Wiegand SB, Jaroszewicz J, et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015; 21: 606 e1-e10.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D"}, "refd-itemidlist": {"itemid": {"$": "84930788875", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "21"}, "pagerange": {"@first": "606"}}, "ref-text": "e1-60610", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Maasoumy", "ce:indexed-name": "Maasoumy B."}, {"@seq": "2", "ce:initials": "S.B.", "@_fa": "true", "ce:surname": "Wiegand", "ce:indexed-name": "Wiegand S.B."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Jaroszewicz", "ce:indexed-name": "Jaroszewicz J."}], "et-al": null}, "ref-sourcetitle": "Clin Microbiol Infect"}}, {"ref-fulltext": "Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013; 58: 427-33.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis"}, "refd-itemidlist": {"itemid": {"$": "84874111839", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "58"}, "pagerange": {"@first": "427", "@last": "433"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Kumada", "ce:indexed-name": "Kumada T."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Toyoda", "ce:indexed-name": "Toyoda H."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Tada", "ce:indexed-name": "Tada T."}], "et-al": null}, "ref-sourcetitle": "J Hepatol"}}, {"ref-fulltext": "Hosaka T, Suzuki F, Kobayashi M, et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010; 30: 1461-70.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy"}, "refd-itemidlist": {"itemid": {"$": "79951651043", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "30"}, "pagerange": {"@first": "1461", "@last": "1470"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Hosaka", "ce:indexed-name": "Hosaka T."}, {"@seq": "2", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Suzuki", "ce:indexed-name": "Suzuki F."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Kobayashi", "ce:indexed-name": "Kobayashi M."}], "et-al": null}, "ref-sourcetitle": "Liver Int"}}, {"ref-fulltext": "Matsumoto A, Tanaka E, Morita S, et al. Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection. J Gastroenterol 2012; 47: 1006-13.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection"}, "refd-itemidlist": {"itemid": {"$": "84867577231", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "47"}, "pagerange": {"@first": "1006", "@last": "1013"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Matsumoto", "ce:indexed-name": "Matsumoto A."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Tanaka", "ce:indexed-name": "Tanaka E."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Morita", "ce:indexed-name": "Morita S."}], "et-al": null}, "ref-sourcetitle": "J Gastroenterol"}}, {"ref-fulltext": "Okuhara S, Umemura T, Joshita S, et al. Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatol Res 2014; 44: E172-80.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84907880114", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "44"}, "pagerange": {"@first": "E172", "@last": "E180"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Okuhara", "ce:indexed-name": "Okuhara S."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Umemura", "ce:indexed-name": "Umemura T."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Joshita", "ce:indexed-name": "Joshita S."}], "et-al": null}, "ref-sourcetitle": "Hepatol Res"}}, {"ref-fulltext": "Matsumoto A, Tanaka E, Minami M, et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res 2007; 37: 661-6.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy"}, "refd-itemidlist": {"itemid": {"$": "34347327086", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "37"}, "pagerange": {"@first": "661", "@last": "666"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Matsumoto", "ce:indexed-name": "Matsumoto A."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Tanaka", "ce:indexed-name": "Tanaka E."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Minami", "ce:indexed-name": "Minami M."}], "et-al": null}, "ref-sourcetitle": "Hepatol Res"}}, {"ref-fulltext": "EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Management of chronic hepatitis B virus infection"}, "refd-itemidlist": {"itemid": {"$": "84862664371", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "57"}, "pagerange": {"@first": "167", "@last": "185"}}, "ref-authors": {"collaboration": {"@seq": "1", "ce:text": "EASL clinical practice guidelines", "ce:indexed-name": "EASL clinical practice guidelines"}}, "ref-sourcetitle": "J Hepatol"}}, {"ref-fulltext": "Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "1996"}, "ref-title": {"ref-titletext": "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group"}, "refd-itemidlist": {"itemid": {"$": "0029778988", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "24"}, "pagerange": {"@first": "289", "@last": "293"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Bedossa", "ce:indexed-name": "Bedossa P."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Poynard", "ce:indexed-name": "Poynard T."}]}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Tangkijvanich P, Sa-Nguanmoo P, Mahachai V, Theamboonlers A, Poovorawan Y. A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int 2010; 4: 577-84.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma"}, "refd-itemidlist": {"itemid": {"$": "77958090656", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "4"}, "pagerange": {"@first": "577", "@last": "584"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Sa-Nguanmoo", "ce:indexed-name": "Sa-Nguanmoo P."}, {"@seq": "3", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Mahachai", "ce:indexed-name": "Mahachai V."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Theamboonlers", "ce:indexed-name": "Theamboonlers A."}, {"@seq": "5", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Poovorawan", "ce:indexed-name": "Poovorawan Y."}]}, "ref-sourcetitle": "Hepatol Int"}}, {"ref-fulltext": "Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002; 40: 439-45.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load"}, "refd-itemidlist": {"itemid": {"$": "0036159549", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "40"}, "pagerange": {"@first": "439", "@last": "445"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Kimura", "ce:indexed-name": "Kimura T."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Rokuhara", "ce:indexed-name": "Rokuhara A."}, {"@seq": "3", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Sakamoto", "ce:indexed-name": "Sakamoto Y."}], "et-al": null}, "ref-sourcetitle": "J Clin Microbiol"}}, {"ref-fulltext": "Malmstrom S, Larsson SB, Hannoun C, Lindh M. Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load-down-regulated transcription of PgRNA has limited impact. PLoS ONE 2012; 7: e36349.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load-down-regulated transcription of PgRNA has limited impact"}, "refd-itemidlist": {"itemid": {"$": "84864094505", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7"}, "pagerange": {"@first": "e36349"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Malmstrom", "ce:indexed-name": "Malmstrom S."}, {"@seq": "2", "ce:initials": "S.B.", "@_fa": "true", "ce:surname": "Larsson", "ce:indexed-name": "Larsson S.B."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Hannoun", "ce:indexed-name": "Hannoun C."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lindh", "ce:indexed-name": "Lindh M."}]}, "ref-sourcetitle": "PLoS ONE"}}, {"ref-fulltext": "Sung JJ, Wong M-L, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-7.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy"}, "refd-itemidlist": {"itemid": {"$": "20444505037", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "128"}, "pagerange": {"@first": "1890", "@last": "1897"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.J.", "@_fa": "true", "ce:surname": "Sung", "ce:indexed-name": "Sung J.J."}, {"@seq": "2", "ce:initials": "M.-L.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong M.-L."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Bowden", "ce:indexed-name": "Bowden S."}], "et-al": null}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147: 58-61.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points"}, "refd-itemidlist": {"itemid": {"$": "34447259615", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "147"}, "pagerange": {"@first": "58", "@last": "61"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.L.", "@_fa": "true", "ce:surname": "Lai", "ce:indexed-name": "Lai C.L."}, {"@seq": "2", "ce:initials": "M.F.", "@_fa": "true", "ce:surname": "Yuen", "ce:indexed-name": "Yuen M.F."}]}, "ref-sourcetitle": "Ann Intern Med"}}, {"ref-fulltext": "Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma"}, "refd-itemidlist": {"itemid": {"$": "53549107488", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "28"}, "pagerange": {"@first": "1067", "@last": "1077"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.J.", "@_fa": "true", "ce:surname": "Sung", "ce:indexed-name": "Sung J.J."}, {"@seq": "2", "ce:initials": "K.K.", "@_fa": "true", "ce:surname": "Tsoi", "ce:indexed-name": "Tsoi K.K."}, {"@seq": "3", "ce:initials": "V.W.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong V.W."}, {"@seq": "4", "ce:initials": "K.C.", "@_fa": "true", "ce:surname": "Li", "ce:indexed-name": "Li K.C."}, {"@seq": "5", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Chan", "ce:indexed-name": "Chan H.L."}]}, "ref-sourcetitle": "Aliment Pharmacol Ther"}}, {"ref-fulltext": "Yang YF, Zhao W, Zhong YD, et al. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009; 16: 265-71.", "@id": "27", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis"}, "refd-itemidlist": {"itemid": {"$": "61449187479", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "16"}, "pagerange": {"@first": "265", "@last": "271"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.F.", "@_fa": "true", "ce:surname": "Yang", "ce:indexed-name": "Yang Y.F."}, {"@seq": "2", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Zhao", "ce:indexed-name": "Zhao W."}, {"@seq": "3", "ce:initials": "Y.D.", "@_fa": "true", "ce:surname": "Zhong", "ce:indexed-name": "Zhong Y.D."}], "et-al": null}, "ref-sourcetitle": "J Viral Hepat"}}, {"ref-fulltext": "Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.", "@id": "28", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial"}, "refd-itemidlist": {"itemid": {"$": "19944428132", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "365"}, "pagerange": {"@first": "123", "@last": "129"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Janssen", "ce:indexed-name": "Janssen H.L."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "van Zonneveld", "ce:indexed-name": "van Zonneveld M."}, {"@seq": "3", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Senturk", "ce:indexed-name": "Senturk H."}], "et-al": null}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.", "@id": "29", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "21244447705", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "352"}, "pagerange": {"@first": "2682", "@last": "2695"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.K.", "@_fa": "true", "ce:surname": "Lau", "ce:indexed-name": "Lau G.K."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Piratvisuth", "ce:indexed-name": "Piratvisuth T."}, {"@seq": "3", "ce:initials": "K.X.", "@_fa": "true", "ce:surname": "Luo", "ce:indexed-name": "Luo K.X."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.", "@id": "30", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline"}, "refd-itemidlist": {"itemid": {"$": "77957958049", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "52"}, "pagerange": {"@first": "1251", "@last": "1257"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Sonneveld", "ce:indexed-name": "Sonneveld M.J."}, {"@seq": "2", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Rijckborst", "ce:indexed-name": "Rijckborst V."}, {"@seq": "3", "ce:initials": "C.A.", "@_fa": "true", "ce:surname": "Boucher", "ce:indexed-name": "Boucher C.A."}, {"@seq": "4", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Hansen", "ce:indexed-name": "Hansen B.E."}, {"@seq": "5", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Janssen", "ce:indexed-name": "Janssen H.L."}]}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2013; 7: 429-36.", "@id": "31", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients"}, "refd-itemidlist": {"itemid": {"$": "84879841799", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7"}, "pagerange": {"@first": "429", "@last": "436"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Piratvisuth", "ce:indexed-name": "Piratvisuth T."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Marcellin", "ce:indexed-name": "Marcellin P."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Popescu", "ce:indexed-name": "Popescu M."}], "et-al": null}, "ref-sourcetitle": "Hepatol Int"}}, {"ref-fulltext": "Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013; 7: 88-97.", "@id": "32", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients"}, "refd-itemidlist": {"itemid": {"$": "84875279880", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7"}, "pagerange": {"@first": "88", "@last": "97"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Marcellin", "ce:indexed-name": "Marcellin P."}, {"@seq": "2", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Bonino", "ce:indexed-name": "Bonino F."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Yurdaydin", "ce:indexed-name": "Yurdaydin C."}], "et-al": null}, "ref-sourcetitle": "Hepatol Int"}}, {"ref-fulltext": "Seto WK, Tanaka Y, Wong DK, et al. Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatol Int 2012; 7: 98-105.", "@id": "33", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay"}, "refd-itemidlist": {"itemid": {"$": "84875241425", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7"}, "pagerange": {"@first": "98", "@last": "105"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.K.", "@_fa": "true", "ce:surname": "Seto", "ce:indexed-name": "Seto W.K."}, {"@seq": "2", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Tanaka", "ce:indexed-name": "Tanaka Y."}, {"@seq": "3", "ce:initials": "D.K.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong D.K."}], "et-al": null}, "ref-sourcetitle": "Hepatol Int"}}, {"ref-fulltext": "Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82.", "@id": "34", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels"}, "refd-itemidlist": {"itemid": {"$": "33847410055", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "12"}, "pagerange": {"@first": "73", "@last": "82"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.K.", "@_fa": "true", "ce:surname": "Manesis", "ce:indexed-name": "Manesis E.K."}, {"@seq": "2", "ce:initials": "E.S.", "@_fa": "true", "ce:surname": "Hadziyannis", "ce:indexed-name": "Hadziyannis E.S."}, {"@seq": "3", "ce:initials": "O.P.", "@_fa": "true", "ce:surname": "Angelopoulou", "ce:indexed-name": "Angelopoulou O.P."}, {"@seq": "4", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Hadziyannis", "ce:indexed-name": "Hadziyannis S.J."}]}, "ref-sourcetitle": "Antivir Ther"}}, {"ref-fulltext": "Sonneveld MJ, Rijckborst V, Zeuzem S, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2012; 56: 67-75.", "@id": "35", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84863517149", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56"}, "pagerange": {"@first": "67", "@last": "75"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Sonneveld", "ce:indexed-name": "Sonneveld M.J."}, {"@seq": "2", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Rijckborst", "ce:indexed-name": "Rijckborst V."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Zeuzem", "ce:indexed-name": "Zeuzem S."}], "et-al": null}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol 2013b; 58: 898-903.", "@id": "36", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84876284069", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "58"}, "pagerange": {"@first": "898", "@last": "903"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Sonneveld", "ce:indexed-name": "Sonneveld M.J."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Arends", "ce:indexed-name": "Arends P."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Boonstra", "ce:indexed-name": "Boonstra A."}, {"@seq": "4", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Hansen", "ce:indexed-name": "Hansen B.E."}, {"@seq": "5", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Janssen", "ce:indexed-name": "Janssen H.L."}]}, "ref-sourcetitle": "J Hepatol"}}, {"ref-fulltext": "Jazayeri SM, Alavian SM, Carman WF. Hepatitis B virus: origin and evolution. J Viral Hepat 2010; 17: 229-35.", "@id": "37", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Hepatitis B virus: origin and evolution"}, "refd-itemidlist": {"itemid": {"$": "77950280936", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "17"}, "pagerange": {"@first": "229", "@last": "235"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.M.", "@_fa": "true", "ce:surname": "Jazayeri", "ce:indexed-name": "Jazayeri S.M."}, {"@seq": "2", "ce:initials": "S.M.", "@_fa": "true", "ce:surname": "Alavian", "ce:indexed-name": "Alavian S.M."}, {"@seq": "3", "ce:initials": "W.F.", "@_fa": "true", "ce:surname": "Carman", "ce:indexed-name": "Carman W.F."}]}, "ref-sourcetitle": "J Viral Hepat"}}]}}}}, "affiliation": [{"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, {"affiliation-city": "Nagoya", "@id": "60004321", "affilname": "Nagoya City University Graduate School of Medical Sciences", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004321", "affiliation-country": "Japan"}], "coredata": {"srctype": "j", "eid": "2-s2.0-84966783616", "dc:description": "Background & Aims: The role of quantitative serum hepatitis B core-related antigen (HBcrAg) in patients with chronic hepatitis B (CHB) receiving pegylated interferon (PEG-IFN) is unclear. This study was aimed at comparing its usefulness with quantitative HBsAg in patients with HBeAg-positive CHB receiving PEG-IFN therapy. Methods: A total 46 patients treated with PEG-IFN for 48 weeks were retrospectively analysed. Intrahepatic covalently closed circular DNA (cccDNA) from paired liver biopsies and serial serum HBsAg and HBcrAg during therapy were assessed. Results: Virological response (VR), defined as HBeAg clearance and HBV DNA <2000 IU/ml at 24 weeks post treatment, was achieved in 15 (32.6%) patients. Responders had significantly higher cccDNA decline from baseline compared with non-responders. Baseline HBsAg and HBcrAg were correlated with cccDNA (r = 0.424, P = 0.020 and r = 0.564, P = 0.001, respectively), and changes in the corresponding markers during therapy were correlated with cccDNA reduction (r = 0.579, P = 0.001 and r = 0.503, P = 0.005, respectively). Responders showed more rapid decline of both markers during therapy compared with non-responders. In multivariate analysis, serum HBcrAg at week 12 was identified as a predictor of VR. The optimal cut-off value for HBcrAg (log10 8.0 U/ml) provided negative predictive value (NPV) of achieving VR at weeks 12 and 24 of 94.4 and 100%, respectively, while using HBsAg > 20 000 IU/ml provided NPV of 80 and 100% respectively. Conclusions: The convenient quantitative HBcrAg represented a reliable marker of intrahepatic cccDNA. Monitoring HBcrAg levels during PEG-IFN therapy may help identify patients with a very low probability of response comparable to, if not better than, quantitative HBsAg.", "pubmed-id": "26678018", "prism:coverDate": "2016-06-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/84966783616", "dc:creator": {"author": [{"ce:given-name": "Natthaya", "preferred-name": {"ce:given-name": "Natthaya", "ce:initials": "N.", "ce:surname": "Chuaypen", "ce:indexed-name": "Chuaypen N."}, "@seq": "1", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Chuaypen", "@auid": "55885029700", "author-url": "https://api.elsevier.com/content/author/author_id/55885029700", "ce:indexed-name": "Chuaypen N."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/84966783616"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84966783616&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84966783616&origin=inward"}], "source-id": "25321", "citedby-count": "63", "prism:volume": "36", "subtype": "ar", "dc:title": "Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B", "openaccess": "0", "prism:issn": "14783231 14783223", "publishercopyright": "\u00a9 2016 John Wiley & Sons A/S.", "prism:issueIdentifier": "6", "subtypeDescription": "Article", "prism:publicationName": "Liver International", "prism:pageRange": "827-836", "prism:endingPage": "836", "openaccessFlag": "false", "prism:doi": "10.1111/liv.13046", "prism:startingPage": "827", "dc:identifier": "SCOPUS_ID:84966783616", "dc:publisher": "Blackwell Publishing Ltdcustomerservices@oxonblackwellpublishing.com"}, "idxterms": {"mainterm": [{"$": "Adult", "@weight": "b", "@candidate": "n"}, {"$": "Antiviral Agents", "@weight": "b", "@candidate": "n"}, {"$": "Biomarkers", "@weight": "b", "@candidate": "n"}, {"$": "DNA, Circular", "@weight": "b", "@candidate": "n"}, {"$": "DNA, Viral", "@weight": "b", "@candidate": "n"}, {"$": "Female", "@weight": "b", "@candidate": "n"}, {"$": "Hepatitis B Core Antigens", "@weight": "b", "@candidate": "n"}, {"$": "Hepatitis B e Antigens", "@weight": "b", "@candidate": "n"}, {"$": "Hepatitis B Surface Antigens", "@weight": "b", "@candidate": "n"}, {"$": "Hepatitis B virus", "@weight": "b", "@candidate": "n"}, {"$": "Hepatitis B, Chronic", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "Interferons", "@weight": "b", "@candidate": "n"}, {"$": "Liver", "@weight": "b", "@candidate": "n"}, {"$": "Logistic Models", "@weight": "b", "@candidate": "n"}, {"$": "Male", "@weight": "b", "@candidate": "n"}, {"$": "Multivariate Analysis", "@weight": "b", "@candidate": "n"}, {"$": "ROC Curve", "@weight": "b", "@candidate": "n"}, {"$": "Sustained Virologic Response", "@weight": "b", "@candidate": "n"}, {"$": "Thailand", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": {"author-keyword": [{"@_fa": "true", "$": "HBsAg quantification"}, {"@_fa": "true", "$": "Hepatitis B core-related antigen"}, {"@_fa": "true", "$": "Hepatitis B virus"}, {"@_fa": "true", "$": "Pegylated interferon"}]}, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Hepatology", "@code": "2721", "@abbrev": "MEDI"}]}, "authors": {"author": [{"ce:given-name": "Natthaya", "preferred-name": {"ce:given-name": "Natthaya", "ce:initials": "N.", "ce:surname": "Chuaypen", "ce:indexed-name": "Chuaypen N."}, "@seq": "1", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Chuaypen", "@auid": "55885029700", "author-url": "https://api.elsevier.com/content/author/author_id/55885029700", "ce:indexed-name": "Chuaypen N."}, {"ce:given-name": "Nawarat", "preferred-name": {"ce:given-name": "Nawarat", "ce:initials": "N.", "ce:surname": "Posuwan", "ce:indexed-name": "Posuwan N."}, "@seq": "2", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Posuwan", "@auid": "26653756700", "author-url": "https://api.elsevier.com/content/author/author_id/26653756700", "ce:indexed-name": "Posuwan N."}, {"ce:given-name": "Sunchai", "preferred-name": {"ce:given-name": "Sunchai", "ce:initials": "S.", "ce:surname": "Payungporn", "ce:indexed-name": "Payungporn S."}, "@seq": "3", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Payungporn", "@auid": "6507400304", "author-url": "https://api.elsevier.com/content/author/author_id/6507400304", "ce:indexed-name": "Payungporn S."}, {"ce:given-name": "Yasuhito", "preferred-name": {"ce:given-name": "Yasuhito", "ce:initials": "Y.", "ce:surname": "Tanaka", "ce:indexed-name": "Tanaka Y."}, "@seq": "4", "ce:initials": "Y.", "@_fa": "true", "affiliation": {"@id": "60004321", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004321"}, "ce:surname": "Tanaka", "@auid": "7405315865", "author-url": "https://api.elsevier.com/content/author/author_id/7405315865", "ce:indexed-name": "Tanaka Y."}, {"ce:given-name": "Noboru", "preferred-name": {"ce:given-name": "Noboru", "ce:initials": "N.", "ce:surname": "Shinkai", "ce:indexed-name": "Shinkai N."}, "@seq": "5", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60004321", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004321"}, "ce:surname": "Shinkai", "@auid": "7003826116", "author-url": "https://api.elsevier.com/content/author/author_id/7003826116", "ce:indexed-name": "Shinkai N."}, {"ce:given-name": "Yong", "preferred-name": {"ce:given-name": "Yong", "ce:initials": "Y.", "ce:surname": "Poovorawan", "ce:indexed-name": "Poovorawan Y."}, "@seq": "6", "ce:initials": "Y.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Poovorawan", "@auid": "7102786191", "author-url": "https://api.elsevier.com/content/author/author_id/7102786191", "ce:indexed-name": "Poovorawan Y."}, {"ce:given-name": "Pisit", "preferred-name": {"ce:given-name": "Pisit", "ce:initials": "P.", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}, "@seq": "7", "ce:initials": "P.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "M.D", "ce:surname": "Tangkijvanich", "@auid": "7003646635", "author-url": "https://api.elsevier.com/content/author/author_id/7003646635", "ce:indexed-name": "Tangkijvanich P."}]}}}